Table of Contents Author Guidelines Submit a Manuscript
Stem Cells International
Volume 2016, Article ID 6193419, 17 pages
http://dx.doi.org/10.1155/2016/6193419
Review Article

Repair Injured Heart by Regulating Cardiac Regenerative Signals

1Department of Pathology & Lab Medicine, College of Medicine, University of Cincinnati, Cincinnati, OH 45267, USA
2Department of Pharmacology & Cell Biophysics, College of Medicine, University of Cincinnati, Cincinnati, OH 45267, USA
3Infectious Disease Hospital, Nanchang University, Nanchang, Jiangxi 330002, China

Received 16 March 2016; Revised 27 June 2016; Accepted 29 June 2016

Academic Editor: Benedetta Bussolati

Copyright © 2016 Wen-Feng Cai et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. N. J. Palpant and C. E. Murry, “Proliferation at the heart of preadolescence,” Cell, vol. 157, no. 4, pp. 765–767, 2014. View at Publisher · View at Google Scholar · View at Scopus
  2. N. Naqvi, M. Li, J. W. Calvert et al., “A proliferative burst during preadolescence establishes the final cardiomyocyte number,” Cell, vol. 157, no. 4, pp. 795–807, 2014. View at Publisher · View at Google Scholar · View at Scopus
  3. N. N. Chattergoon, G. D. Giraud, S. Louey, P. Stork, A. L. Fowden, and K. L. Thornburg, “Thyroid hormone drives fetal cardiomyocyte maturation,” The FASEB Journal, vol. 26, no. 1, pp. 397–408, 2012. View at Publisher · View at Google Scholar · View at Scopus
  4. X. Yang, M. Rodriguez, L. Pabon et al., “Tri-iodo-L-thyronine promotes the maturation of human cardiomyocytes-derived from induced pluripotent stem cells,” Journal of Molecular and Cellular Cardiology, vol. 72, pp. 296–304, 2014. View at Publisher · View at Google Scholar · View at Scopus
  5. X. Li, A. J. Misik, C. V. Rieder, R. J. Solaro, A. Lowen, and L. Fliegel, “Thyroid hormone receptor α1 regulates expression of the Na+/H+ exchanger (NHE1),” The Journal of Biological Chemistry, vol. 277, no. 32, pp. 28656–28662, 2002. View at Publisher · View at Google Scholar · View at Scopus
  6. H. Alonso, J. Fernández-Ruocco, M. Gallego et al., “Thyroid stimulating hormone directly modulates cardiac electrical activity,” Journal of Molecular and Cellular Cardiology, vol. 89, pp. 280–286, 2015. View at Publisher · View at Google Scholar · View at Scopus
  7. L. Xie, X. Pi, W. H. D. Townley-Tilson et al., “PHD2/3-dependent hydroxylation tunes cardiac response to β-adrenergic stress via phospholamban,” The Journal of Clinical Investigation, vol. 125, no. 7, pp. 2759–2771, 2015. View at Publisher · View at Google Scholar · View at Scopus
  8. K. M. Wadosky, J. M. Berthiaume, W. Tang et al., “MuRF1 mono-ubiquitinates TRα to inhibit T3-induced cardiac hypertrophy in vivo,” Journal of Molecular Endocrinology, vol. 56, no. 3, pp. 273–290, 2016. View at Publisher · View at Google Scholar
  9. Y.-Y. Liu, T. Kogai, J. J. Schultz, K. Mody, and G. A. Brent, “Thyroid hormone receptor isoform-specific modification by small ubiquitin-like modifier (SUMO) modulates thyroid hormone-dependent gene regulation,” The Journal of Biological Chemistry, vol. 287, no. 43, pp. 36499–36508, 2012. View at Publisher · View at Google Scholar · View at Scopus
  10. A. P. C. Takano, G. P. Diniz, and M. L. M. Barreto-Chaves, “AMPK signaling pathway is rapidly activated by T3 and regulates the cardiomyocyte growth,” Molecular and Cellular Endocrinology, vol. 376, no. 1-2, pp. 43–50, 2013. View at Publisher · View at Google Scholar · View at Scopus
  11. C. Pantos, C. Xinaris, I. Mourouzis, V. Malliopoulou, E. Kardami, and D. V. Cokkinos, “Thyroid hormone changes cardiomyocyte shape and geometry via ERK signaling pathway: potential therapeutic implications in reversing cardiac remodeling?” Molecular and Cellular Biochemistry, vol. 297, no. 1-2, pp. 65–72, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. A. Iordanidou, M. Hadzopoulou-Cladaras, and A. Lazou, “Non-genomic effects of thyroid hormone in adult cardiac myocytes: relevance to gene expression and cell growth,” Molecular and Cellular Biochemistry, vol. 340, no. 1-2, pp. 291–300, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. N. N. Chattergoon, S. Louey, P. J. Stork, G. D. Giraud, and K. L. Thornburg, “Unexpected maturation of PI3K and MAPK-ERK signaling in fetal ovine cardiomyocytes,” American Journal of Physiology—Heart and Circulatory Physiology, vol. 307, no. 8, pp. H1216–H1225, 2014. View at Publisher · View at Google Scholar · View at Scopus
  14. A. J. Forhead and A. L. Fowden, “Thyroid hormones in fetal growth and prepartum maturation,” Journal of Endocrinology, vol. 221, no. 3, pp. R87–R103, 2014. View at Publisher · View at Google Scholar · View at Scopus
  15. F. Forini, C. Kusmic, G. Nicolini et al., “Triiodothyronine prevents cardiac ischemia/reperfusion mitochondrial impairment and cell loss by regulating miR30a/p53 axis,” Endocrinology, vol. 155, no. 11, pp. 4581–4590, 2014. View at Publisher · View at Google Scholar · View at Scopus
  16. C. Pantos, I. Mourouzis, T. Saranteas et al., “Acute T3 treatment protects the heart against ischemia-reperfusion injury via TRα1 receptor,” Molecular and Cellular Biochemistry, vol. 353, no. 1-2, pp. 235–241, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. I. Mourouzis, E. Kostakou, G. Galanopoulos, P. Mantzouratou, and C. Pantos, “Inhibition of thyroid hormone receptor α1 impairs post-ischemic cardiac performance after myocardial infarction in mice,” Molecular and Cellular Biochemistry, vol. 379, no. 1-2, pp. 97–105, 2013. View at Publisher · View at Google Scholar · View at Scopus
  18. E. Alonso-Merino, R. Martín Orozco, L. Ruíz-Llorente et al., “Thyroid hormones inhibit TGF-β signaling and attenuate fibrotic responses,” Proceedings of the National Academy of Sciences of the United States of America, vol. 113, no. 24, pp. E3451–E3460, 2016. View at Publisher · View at Google Scholar
  19. Y. Zhang, E. I. Dedkov, B. Lee, Y. Li, K. Pun, and A. M. Gerdes, “Thyroid hormone replacement therapy attenuates atrial remodeling and reduces atrial fibrillation inducibility in a rat myocardial infarction-heart failure model,” Journal of Cardiac Failure, vol. 20, no. 12, pp. 1012–1019, 2014. View at Publisher · View at Google Scholar · View at Scopus
  20. A. Pingitore, Y. Chen, A. M. Gerdes, and G. Iervasi, “Acute myocardial infarction and thyroid function: new pathophysiological and therapeutic perspectives,” Annals of Medicine, vol. 44, no. 8, pp. 745–757, 2012. View at Publisher · View at Google Scholar · View at Scopus
  21. N. Naderi, M. Heidarali, F. Barzegari, B. Ghadrdoost, A. Amin, and S. Taghavi, “Hormonal profile in patients with dilated cardiomyopathy,” Research in Cardiovascular Medicine, vol. 4, no. 3, Article ID e27631, 2015. View at Publisher · View at Google Scholar
  22. L. Friberg, V. Drvota, A. H. Bjelak, G. Eggertsen, and S. Ahnve, “Association between increased levels of reverse triiodothyronine and mortality after acute myocardial infarction,” American Journal of Medicine, vol. 111, no. 9, pp. 699–703, 2001. View at Publisher · View at Google Scholar · View at Scopus
  23. A. Pingitore, E. Galli, A. Barison et al., “Acute effects of triiodothyronine (T3) replacement therapy in patients with chronic heart failure and low-T3 syndrome: a randomized, placebo-controlled study,” The Journal of Clinical Endocrinology and Metabolism, vol. 93, no. 4, pp. 1351–1358, 2008. View at Publisher · View at Google Scholar · View at Scopus
  24. S. Goldman, M. McCarren, E. Morkin et al., “DITPA (3,5-diiodothyropropionic acid), a thyroid hormone analog to treat heart failure: phase II trial veterans affairs cooperative study,” Circulation, vol. 119, no. 24, pp. 3093–3100, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. P. Holmager, U. Schmidt, P. Mark et al., “Long-term L-Triiodothyronine (T3) treatment in stable systolic heart failure patients: a randomised, double-blind, cross-over, placebo-controlled intervention study,” Clinical Endocrinology, vol. 83, no. 6, pp. 931–937, 2015. View at Publisher · View at Google Scholar · View at Scopus
  26. X. Liu, R. Bates, D.-M. Yin et al., “Specific regulation of NRG1 isoform expression by neuronal activity,” The Journal of Neuroscience, vol. 31, no. 23, pp. 8491–8501, 2011. View at Publisher · View at Google Scholar · View at Scopus
  27. I. Lundgaard, A. Luzhynskaya, J. H. Stockley et al., “Neuregulin and BDNF induce a switch to NMDA receptor-dependent myelination by oligodendrocytes,” PLoS Biology, vol. 11, no. 12, Article ID e1001743, 2013. View at Publisher · View at Google Scholar · View at Scopus
  28. M. S. Mostaid, D. Lloyd, B. Liberg et al., “Neuregulin-1 and schizophrenia in the genome-wide association study era,” Neuroscience & Biobehavioral Reviews, vol. 68, pp. 387–409, 2016. View at Publisher · View at Google Scholar
  29. Y. Hama, I. Yabe, K. Wakabayashi et al., “Level of plasma neuregulin-1 SMDF is reduced in patients with idiopathic Parkinson's disease,” Neuroscience Letters, vol. 587, pp. 17–21, 2015. View at Publisher · View at Google Scholar · View at Scopus
  30. K. A. Chang, K. Y. Shin, E. Nam et al., “Plasma soluble neuregulin-1 as a diagnostic biomarker for Alzheimer's disease,” Neurochemistry International, vol. 97, pp. 1–7, 2016. View at Publisher · View at Google Scholar
  31. H. Gui, W. K. Tang, M. T. So et al., “RET and NRG1 interplay in Hirschsprung disease,” Human Genetics, vol. 132, no. 5, pp. 591–600, 2013. View at Google Scholar
  32. Y.-F. Guan, C.-Y. Wu, Y.-Y. Fang et al., “Neuregulin 1 protects against ischemic brain injury via ErbB4 receptors by increasing GABAergic transmission,” Neuroscience, vol. 307, pp. 151–159, 2015. View at Publisher · View at Google Scholar · View at Scopus
  33. M. Engel, P. Snikeris, A. Jenner, T. Karl, X.-F. Huang, and E. Frank, “Neuregulin 1 prevents phencyclidine-induced behavioral impairments and disruptions to GABAergic signaling in mice,” The International Journal of Neuropsychopharmacology, vol. 18, no. 7, Article ID pyu114, 2015. View at Publisher · View at Google Scholar
  34. M. Chen, L.-L. Bi, Z.-Q. Wang, F. Zhao, X.-D. Gan, and Y.-G. Wang, “Time-dependent regulation of neuregulin-1β/ErbB/ERK pathways in cardiac differentiation of mouse embryonic stem cells,” Molecular and Cellular Biochemistry, vol. 380, no. 1-2, pp. 67–72, 2013. View at Publisher · View at Google Scholar · View at Scopus
  35. L. Pentassuglia, P. Heim, S. Lebboukh, C. Morandi, L. Xu, and M. Brink, “Neuregulin-1β promotes glucose uptake via PI3K/Akt in neonatal rat cardiomyocytes,” American Journal of Physiology—Endocrinology and Metabolism, vol. 310, no. 9, pp. E782–E794, 2016. View at Publisher · View at Google Scholar
  36. B. Jie, X. Zhang, X. Wu, Y. Xin, Y. Liu, and Y. Guo, “Neuregulin-1 suppresses cardiomyocyte apoptosis by activating PI3K/Akt and inhibiting mitochondrial permeability transition pore,” Molecular and Cellular Biochemistry, vol. 370, no. 1-2, pp. 35–43, 2012. View at Publisher · View at Google Scholar · View at Scopus
  37. Y. Kuramochi, X. Guo, and D. B. Sawyer, “Neuregulin activates erbB2-dependent src/FAK signaling and cytoskeletal remodeling in isolated adult rat cardiac myocytes,” Journal of Molecular and Cellular Cardiology, vol. 41, no. 2, pp. 228–235, 2006. View at Publisher · View at Google Scholar · View at Scopus
  38. L. Pentassuglia, M. Graf, H. Lane et al., “Inhibition of ErbB2 by receptor tyrosine kinase inhibitors causes myofibrillar structural damage without cell death in adult rat cardiomyocytes,” Experimental Cell Research, vol. 315, no. 7, pp. 1302–1312, 2009. View at Publisher · View at Google Scholar · View at Scopus
  39. A. Brero, R. Ramella, A. Fitou et al., “Neuregulin-1β1 rapidly modulates nitric oxide synthesis and calcium handling in rat cardiomyocytes,” Cardiovascular Research, vol. 88, no. 3, pp. 443–452, 2010. View at Publisher · View at Google Scholar · View at Scopus
  40. L. Pentassuglia and D. B. Sawyer, “ErbB/integrin signaling interactions in regulation of myocardial cell-cell and cell-matrix interactions,” Biochimica et Biophysica Acta—Molecular Cell Research, vol. 1833, no. 4, pp. 909–916, 2013. View at Publisher · View at Google Scholar · View at Scopus
  41. M. E. McCormick, C. Collins, C. A. Makarewich et al., “Platelet endothelial cell adhesion molecule-1 mediates endothelial-cardiomyocyte communication and regulates cardiac function,” Journal of the American Heart Association, vol. 4, no. 1, Article ID e001210, 2014. View at Publisher · View at Google Scholar
  42. G. D'Uva, A. Aharonov, M. Lauriola et al., “ERBB2 triggers mammalian heart regeneration by promoting cardiomyocyte dedifferentiation and proliferation,” Nature Cell Biology, vol. 17, no. 5, pp. 627–638, 2015. View at Publisher · View at Google Scholar · View at Scopus
  43. M. Gemberling, R. Karra, A. L. Dickson, and K. D. Poss, “Nrg1 is an injury-induced cardiomyocyte mitogen for the endogenous heart regeneration program in zebrafish,” eLife, vol. 4, Article ID e05871, 2015. View at Publisher · View at Google Scholar
  44. S. Reischauer, R. Arnaout, R. Ramadass, and D. Y. R. Stainier, “Actin binding GFP allows 4D in vivo imaging of myofilament dynamics in the zebrafish heart and the identification of Erbb2 signaling as a remodeling factor of myofibril architecture,” Circulation Research, vol. 115, no. 10, pp. 845–856, 2014. View at Publisher · View at Google Scholar · View at Scopus
  45. S. Rentschler, J. Zander, K. Meyers et al., “Neuregulin-1 promotes formation of the murine cardiac conduction system,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 16, pp. 10464–10469, 2002. View at Publisher · View at Google Scholar · View at Scopus
  46. G. Tenin, C. Clowes, K. Wolton et al., “Erbb2 is required for cardiac atrial electrical activity during development,” PLoS ONE, vol. 9, no. 9, Article ID e107041, 2014. View at Publisher · View at Google Scholar · View at Scopus
  47. C. E. Rupert and K. L. K. Coulombe, “The roles of neuregulin-1 in cardiac development, homeostasis, and disease,” Biomarker Insights, vol. 10, supplement 1, pp. 1–9, 2015. View at Publisher · View at Google Scholar · View at Scopus
  48. B. D. Polizzotti, B. Ganapathy, S. Walsh et al., “Neuregulin stimulation of cardiomyocyte regeneration in mice and human myocardium reveals a therapeutic window,” Science Translational Medicine, vol. 7, no. 281, Article ID 281ra45, 2015. View at Publisher · View at Google Scholar · View at Scopus
  49. G. M. Cote, D. B. Sawyer, and B. A. Chabner, “ERBB2 inhibition and heart failure,” The New England Journal of Medicine, vol. 367, no. 22, pp. 2150–2153, 2012. View at Publisher · View at Google Scholar · View at Scopus
  50. A. Jabbour, C. S. Hayward, A. M. Keogh et al., “Parenteral administration of recombinant human neuregulin-1 to patients with stable chronic heart failure produces favourable acute and chronic haemodynamic responses,” European Journal of Heart Failure, vol. 13, no. 1, pp. 83–92, 2011. View at Publisher · View at Google Scholar · View at Scopus
  51. R. Gao, J. Zhang, L. Cheng et al., “A phase II, randomized, double-blind, multicenter, based on standard therapy, placebo-controlled study of the efficacy and safety of recombinant human neuregulin-1 in patients with chronic heart failure,” Journal of the American College of Cardiology, vol. 55, no. 18, pp. 1907–1914, 2010. View at Publisher · View at Google Scholar · View at Scopus
  52. Y. Chaly, B. Hostager, S. Smith, and R. Hirsch, “Follistatin-like protein 1 and its role in inflammation and inflammatory diseases,” Immunologic Research, vol. 59, no. 1–3, pp. 266–272, 2014. View at Publisher · View at Google Scholar · View at Scopus
  53. Y. Oshima, N. Ouchi, K. Sato, Y. Izumiya, D. R. Pimentel, and K. Walsh, “Follistatin-like 1 is an Akt-regulated cardioprotective factor that is secreted by the heart,” Circulation, vol. 117, no. 24, pp. 3099–3108, 2008. View at Publisher · View at Google Scholar · View at Scopus
  54. M. Shimano, N. Ouchi, K. Nakamura et al., “Cardiac myocyte follistatin-like 1 functions to attenuate hypertrophy following pressure overload,” Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 43, pp. E899–E906, 2011. View at Publisher · View at Google Scholar · View at Scopus
  55. S. Maruyama, K. Nakamura, K. N. Papanicolaou et al., “Follistatin‐like 1 promotes cardiac fibroblast activation and protects the heart from rupture,” EMBO Molecular Medicine, vol. 8, no. 8, pp. 949–966, 2016. View at Publisher · View at Google Scholar
  56. K. Wei, V. Serpooshan, C. Hurtado et al., “Epicardial FSTL1 reconstitution regenerates the adult mammalian heart,” Nature, vol. 525, no. 7570, pp. 479–485, 2015. View at Publisher · View at Google Scholar · View at Scopus
  57. Y. Ogura, N. Ouchi, K. Ohashi et al., “Therapeutic impact of follistatin-like 1 on myocardial ischemic injury in preclinical models,” Circulation, vol. 126, no. 14, pp. 1728–1738, 2012. View at Publisher · View at Google Scholar · View at Scopus
  58. N. Ouchi, Y. Asaumi, K. Ohashi et al., “DIP2A functions as a FSTL1 receptor,” The Journal of Biological Chemistry, vol. 285, no. 10, pp. 7127–7134, 2010. View at Publisher · View at Google Scholar · View at Scopus
  59. Y. Geng, Y. Dong, M. Yu et al., “Follistatin-like 1 (Fstl1) is a bone morphogenetic protein (BMP) 4 signaling antagonist in controlling mouse lung development,” Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 17, pp. 7058–7063, 2011. View at Publisher · View at Google Scholar · View at Scopus
  60. A. El-Armouche, N. Ouchi, K. Tanaka et al., “Follistatin-like 1 in chronic systolic heart failure: a marker of left ventricular remodeling,” Circulation: Heart Failure, vol. 4, no. 5, pp. 621–627, 2011. View at Publisher · View at Google Scholar · View at Scopus
  61. M. Gorelik, D. C. Wilson, Y. K. Cloonan, S. T. Shulman, and R. Hirsch, “Plasma follistatin-like protein 1 is elevated in Kawasaki disease and may predict coronary artery aneurysm formation,” Journal of Pediatrics, vol. 161, no. 1, pp. 116–119, 2012. View at Publisher · View at Google Scholar · View at Scopus
  62. H. Dhruv, J. C. Loftus, P. Narang et al., “Structural basis and targeting of the interaction between fibroblast growth factor-inducible 14 and tumor necrosis factor-like weak inducer of apoptosis,” The Journal of Biological Chemistry, vol. 288, no. 45, pp. 32261–32276, 2013. View at Publisher · View at Google Scholar · View at Scopus
  63. S. P. F. Ensign, I. T. Mathews, J. M. Eschbacher, J. C. Loftus, M. H. Symons, and N. L. Tran, “The Src homology 3 domain-containing guanine nucleotide exchange factor is overexpressed in high-grade gliomas and promotes tumor necrosis factor-like weak inducer of apoptosis-fibroblast growth factor-inducible 14-induced cell migration and invasion via tumor necrosis factor receptor-associated factor 2,” The Journal of Biological Chemistry, vol. 288, no. 30, pp. 21887–21897, 2013. View at Publisher · View at Google Scholar · View at Scopus
  64. M. Girgenrath, S. Weng, C. A. Kostek et al., “TWEAK, via its receptor Fn14, is a novel regulator of mesenchymal progenitor cells and skeletal muscle regeneration,” The EMBO Journal, vol. 25, no. 24, pp. 5826–5839, 2006. View at Publisher · View at Google Scholar · View at Scopus
  65. S. R. Wiley, L. Cassiano, T. Lofton et al., “A novel TNF receptor family member binds TWEAK and is implicated in angiogenesis,” Immunity, vol. 15, no. 5, pp. 837–846, 2001. View at Publisher · View at Google Scholar · View at Scopus
  66. J. A. Moreno, C. Sastre, J. Madrigal-Matute et al., “HMGB1 expression and secretion are increased via TWEAK-Fn14 interaction in atherosclerotic plaques and cultured monocytes,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 33, no. 3, pp. 612–620, 2013. View at Publisher · View at Google Scholar · View at Scopus
  67. L. C. Burkly, “Regulation of tissue responses: the TWEAK/Fn14 pathway and other TNF/TNFR superfamily members that activate non-canonical NFκB signaling,” Frontiers in Immunology, vol. 6, article 92, 2015. View at Publisher · View at Google Scholar · View at Scopus
  68. E. Chorianopoulos, T. Heger, M. Lutz et al., “FGF-inducible 14-kDa protein (Fn14) is regulated via the RhoA/ROCK kinase pathway in cardiomyocytes and mediates nuclear factor-κB activation by TWEAK,” Basic Research in Cardiology, vol. 105, no. 2, pp. 301–313, 2010. View at Publisher · View at Google Scholar · View at Scopus
  69. T. Novoyatleva, F. Diehl, M. J. van Amerongen et al., “TWEAK is a positive regulator of cardiomyocyte proliferation,” Cardiovascular Research, vol. 85, no. 4, pp. 681–690, 2010. View at Publisher · View at Google Scholar · View at Scopus
  70. T. Novoyatleva, A. Sajjad, D. Pogoryelov, C. Patra, R. T. Schermuly, and F. B. Engel, “FGF1-mediated cardiomyocyte cell cycle reentry depends on the interaction of FGFR-1 and Fn14,” The FASEB Journal, vol. 28, no. 6, pp. 2492–2503, 2014. View at Publisher · View at Google Scholar · View at Scopus
  71. T. Novoyatleva, Y. Schymura, W. Janssen et al., “Deletion of Fn14 receptor protects from right heart fibrosis and dysfunction,” Basic Research in Cardiology, vol. 108, no. 2, article 325, 2013. View at Publisher · View at Google Scholar · View at Scopus
  72. T. Novoyatleva, W. Janssen, A. Wietelmann, R. T. Schermuly, and F. B. Engel, “TWEAK/Fn14 axis is a positive regulator of cardiac hypertrophy,” Cytokine, vol. 64, no. 1, pp. 43–45, 2013. View at Publisher · View at Google Scholar · View at Scopus
  73. C. Pachel, D. Mathes, B. Bayer et al., “Exogenous administration of a recombinant variant of TWEAK impairs healing after myocardial infarction by aggravation of inflammation,” PLoS ONE, vol. 8, no. 11, Article ID e78938, 2013. View at Publisher · View at Google Scholar · View at Scopus
  74. K.-U. Jarr, S. Eschricht, L. C. Burkly et al., “TNF-like weak inducer of apoptosis aggravates left ventricular dysfunction after myocardial infarction in mice,” Mediators of Inflammation, vol. 2014, Article ID 131950, 11 pages, 2014. View at Publisher · View at Google Scholar · View at Scopus
  75. T. Shen, I. Aneas, N. Sakabe et al., “Tbx20 regulates a genetic program essential to adult mouse cardiomyocyte function,” The Journal of Clinical Investigation, vol. 121, no. 12, pp. 4640–4654, 2011. View at Publisher · View at Google Scholar · View at Scopus
  76. F.-L. Xiang, M. Guo, and K. E. Yutzey, “Overexpression of Tbx20 in adult cardiomyocytes promotes proliferation and improves cardiac function after myocardial infarction,” Circulation, vol. 133, no. 11, pp. 1081–1092, 2016. View at Publisher · View at Google Scholar · View at Scopus
  77. Y. Ma, J. Wang, Y. Yu, and R. J. Schwartz, “PKG-1α mediates GATA4 transcriptional activity,” Cellular Signalling, vol. 28, no. 6, pp. 585–594, 2016. View at Publisher · View at Google Scholar
  78. C. Misra, S.-W. Chang, M. Basu, N. Huang, and V. Garg, “Disruption of myocardial Gata4 and Tbx5 results in defects in cardiomyocyte proliferation and atrioventricular septation,” Human Molecular Genetics, vol. 23, no. 19, pp. 5025–5035, 2014. View at Publisher · View at Google Scholar · View at Scopus
  79. W. Yu, X. Huang, X. Tian et al., “GATA4 regulates Fgf16 to promote heart repair after injury,” Development, vol. 143, no. 6, pp. 936–949, 2016. View at Publisher · View at Google Scholar
  80. T. W. Prendiville, H. Guo, Z. Lin et al., “Novel roles of GATA4/6 in the postnatal heart identified through temporally controlled, cardiomyocyte-specific gene inactivation by adeno-associated virus delivery of Cre recombinase,” PLoS ONE, vol. 10, no. 5, Article ID e0128105, 2015. View at Publisher · View at Google Scholar · View at Scopus
  81. S. Usui, Y. Maejima, J. Pain et al., “Endogenous muscle atrophy f-box mediates pressure overload-induced cardiac hypertrophy through regulation of nuclear factor-κB,” Circulation Research, vol. 109, no. 2, pp. 161–171, 2011. View at Publisher · View at Google Scholar · View at Scopus
  82. R. Karra, A. K. Knecht, K. Kikuchi, and K. D. Poss, “Myocardial NF-κB activation is essential for zebrafish heart regeneration,” Proceedings of the National Academy of Sciences of the United States of America, vol. 112, no. 43, pp. 13255–13260, 2015. View at Publisher · View at Google Scholar · View at Scopus
  83. K. Ptaszynska-Kopczynska, M. Marcinkiewicz-Siemion, A. Lisowska et al., “Alterations of soluble TWEAK and CD163 concentrations in patients with chronic heart failure,” Cytokine, vol. 80, pp. 7–12, 2016. View at Publisher · View at Google Scholar
  84. K. Okkenhaug, “Signaling by the phosphoinositide 3-kinase family in immune cells,” Annual Review of Immunology, vol. 31, pp. 675–704, 2013. View at Publisher · View at Google Scholar · View at Scopus
  85. G. W. Dorn II and T. Force, “Protein kinase cascades in the regulation of cardiac hypertrophy,” The Journal of Clinical Investigation, vol. 115, no. 3, pp. 527–537, 2005. View at Publisher · View at Google Scholar · View at Scopus
  86. M. Ichikawa, Y. Sowa, Y. Iizumi, Y. Aono, and T. Sakai, “Resibufogenin induces G1-phase arrest through the proteasomal degradation of cyclin D1 in human malignant tumor cells,” PLoS ONE, vol. 10, no. 6, Article ID e0129851, 2015. View at Publisher · View at Google Scholar · View at Scopus
  87. P. Parekh, L. Motiwale, N. Naik, and K. V. K. Rao, “Downregulation of cyclin D1 is associated with decreased levels of p38 MAP kinases, Akt/PKB and Pak1 during chemopreventive effects of resveratrol in liver cancer cells,” Experimental and Toxicologic Pathology, vol. 63, no. 1-2, pp. 167–173, 2011. View at Publisher · View at Google Scholar · View at Scopus
  88. F. Chang, J. T. Lee, P. M. Navolanic et al., “Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy,” Leukemia, vol. 17, no. 3, pp. 590–603, 2003. View at Publisher · View at Google Scholar · View at Scopus
  89. D. P. Brazil, Z.-Z. Yang, and B. A. Hemmings, “Advances in protein kinase B signalling: AKTion on multiple fronts,” Trends in Biochemical Sciences, vol. 29, no. 5, pp. 233–242, 2004. View at Publisher · View at Google Scholar · View at Scopus
  90. S. Maddika, S. R. Ande, E. Wiechec, L. L. Hansen, S. Wesselborg, and M. Los, “Akt-mediated phosphorylation of CDK2 regulates its dual role in cell cycle progression and apoptosis,” Journal of Cell Science, vol. 121, no. 7, pp. 979–988, 2008. View at Publisher · View at Google Scholar · View at Scopus
  91. F. Beigi, J. Schmeckpeper, P. Pow-Anpongkul et al., “C3orf58, a novel paracrine protein, stimulates cardiomyocyte cell-cycle progression through the PI3K-AKT-CDK7 pathway,” Circulation Research, vol. 113, no. 4, pp. 372–380, 2013. View at Publisher · View at Google Scholar · View at Scopus
  92. H. Zhou, M. E. Dickson, M. S. Kim, R. Bassel-Duby, and E. N. Olson, “Akt1/protein kinase B enhances transcriptional reprogramming of fibroblasts to functional cardiomyocytes,” Proceedings of the National Academy of Sciences of the United States of America, vol. 112, no. 38, pp. 11864–11869, 2015. View at Publisher · View at Google Scholar · View at Scopus
  93. Z. Salah and R. I. Aqeilan, “WW domain interactions regulate the Hippo tumor suppressor pathway,” Cell Death & Disease, vol. 2, article e172, 2011. View at Publisher · View at Google Scholar · View at Scopus
  94. X. Zhou, Z. Wang, W. Huang, and Q.-Y. Lei, “G protein-coupled receptors: bridging the gap from the extracellular signals to the Hippo pathway,” Acta Biochimica et Biophysica Sinica, vol. 47, no. 1, pp. 10–15, 2014. View at Publisher · View at Google Scholar · View at Scopus
  95. W. Tian, J. Yu, D. R. Tomchick, D. Pan, and X. Luo, “Structural and functional analysis of the YAP-binding domain of human TEAD2,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 16, pp. 7293–7298, 2010. View at Publisher · View at Google Scholar · View at Scopus
  96. Z. Li, B. Zhao, P. Wang et al., “Structural insights into the YAP and TEAD complex,” Genes & Development, vol. 24, no. 3, pp. 235–240, 2010. View at Publisher · View at Google Scholar · View at Scopus
  97. J. M. Lamar, P. Stern, H. Liu, J. W. Schindler, Z.-G. Jiang, and R. O. Hynes, “The Hippo pathway target, YAP, promotes metastasis through its TEAD-interaction domain,” Proceedings of the National Academy of Sciences of the United States of America, vol. 109, no. 37, pp. E2441–E2450, 2012. View at Publisher · View at Google Scholar · View at Scopus
  98. Y. Qiao, S. J. Lin, Y. Chen et al., “RUNX3 is a novel negative regulator of oncogenic TEAD–YAP complex in gastric cancer,” Oncogene, vol. 35, no. 20, pp. 2664–2674, 2016. View at Publisher · View at Google Scholar · View at Scopus
  99. Z. Zhou, T. Hu, Z. Xu et al., “Targeting Hippo pathway by specific interruption of YAP-TEAD interaction using cyclic YAP-like peptides,” The FASEB Journal, vol. 29, no. 2, pp. 724–732, 2015. View at Publisher · View at Google Scholar · View at Scopus
  100. M. Xin, Y. Kim, L. B. Sutherland et al., “Regulation of insulin-like growth factor signaling by Yap governs cardiomyocyte proliferation and embryonic heart size,” Science Signaling, vol. 4, no. 196, article ra70, 2011. View at Publisher · View at Google Scholar · View at Scopus
  101. P. Li, Y. Chen, K. K. Mak, C. K. Wong, C. C. Wang, and P. Yuan, “Functional role of MsT1/MsT2 in embryonic stem cell differentiation,” PLoS ONE, vol. 8, no. 11, Article ID e79867, 2013. View at Publisher · View at Google Scholar · View at Scopus
  102. S. D. Lundy, W.-Z. Zhu, M. Regnier, and M. A. Laflamme, “Structural and functional maturation of cardiomyocytes derived from human pluripotent stem cells,” Stem Cells and Development, vol. 22, no. 14, pp. 1991–2002, 2013. View at Publisher · View at Google Scholar · View at Scopus
  103. C. Robertson, D. D. Tran, and S. C. George, “Concise review: maturation phases of human pluripotent stem cell-derived cardiomyocytes,” Stem Cells, vol. 31, no. 5, pp. 829–837, 2013. View at Publisher · View at Google Scholar · View at Scopus
  104. Y. Morikawa, M. Zhang, T. Heallen et al., “Actin cytoskeletal remodeling with protrusion formation is essential for heart regeneration in Hippo-deficient mice,” Science Signaling, vol. 8, no. 375, article ra41, 2015. View at Publisher · View at Google Scholar · View at Scopus
  105. Z. Lin, P. Zhou, A. von Gise et al., “Pi3kcb links Hippo-YAP and PI3K-AKT signaling pathways to promote cardiomyocyte proliferation and survival,” Circulation Research, vol. 116, no. 1, pp. 35–45, 2015. View at Publisher · View at Google Scholar · View at Scopus
  106. I. E. Monroy-Muñoz, N. Pérez-Hernández, J. M. Rodríguez-Pérez et al., “Novel mutations in the transcriptional activator domain of the human TBX20 in patients with atrial septal defect,” BioMed Research International, vol. 2015, Article ID 718786, 7 pages, 2015. View at Publisher · View at Google Scholar · View at Scopus
  107. I. Macindoe, L. Glockner, P. Vukašin et al., “Conformational stability and DNA binding specificity of the cardiac T-box transcription factor Tbx20,” Journal of Molecular Biology, vol. 389, no. 3, pp. 606–618, 2009. View at Publisher · View at Google Scholar · View at Scopus
  108. A. Mittal, R. Sharma, R. Prasad, A. Bahl, and M. Khullar, “Role of cardiac TBX20 in dilated cardiomyopathy,” Molecular and Cellular Biochemistry, vol. 414, no. 1, pp. 129–136, 2016. View at Publisher · View at Google Scholar · View at Scopus
  109. N. El-Hachem and G. Nemer, “Identification of new GATA4-small molecule inhibitors by structure-based virtual screening,” Bioorganic & Medicinal Chemistry, vol. 19, no. 5, pp. 1734–1742, 2011. View at Publisher · View at Google Scholar · View at Scopus
  110. C. Misra, N. Sachan, C. R. McNally et al., “Congenital heart disease-causing Gata4 mutation displays functional deficits in vivo,” PLoS Genetics, vol. 8, no. 5, Article ID e1002690, 2012. View at Publisher · View at Google Scholar · View at Scopus
  111. M. K. Singh, Y. Li, S. Li et al., “Gata4 and Gata5 cooperatively regulate cardiac myocyte proliferation in mice,” The Journal of Biological Chemistry, vol. 285, no. 3, pp. 1765–1772, 2010. View at Publisher · View at Google Scholar · View at Scopus
  112. H. J. Maier, T. G. Schips, A. Wietelmann et al., “Cardiomyocyte-specific IκB kinase (IKK)/NF-κB activation induces reversible inflammatory cardiomyopathy and heart failure,” Proceedings of the National Academy of Sciences of the United States of America, vol. 109, no. 29, pp. 11794–11799, 2012. View at Publisher · View at Google Scholar · View at Scopus